Phase I dose‐escalation study of capmatinib ( INC 280) in Japanese patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I dose‐escalation study of capmatinib ( INC 280) in Japanese patients with advanced solid tumors

Published:2019-02-20 Issue:4 Volume:110 Page:1340-1351
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Esaki Taito¹^ORCID,Hirai Fumihiko¹,Makiyama Akitaka¹,Seto Takashi¹^ORCID,Bando Hideaki²^ORCID,Naito Yoichi²^ORCID,Yoh Kiyotaka²,Ishihara Kae³,Kakizume Tomoyuki³,Natsume Kazuto³,Myers Andrea⁴,Doi Toshihiko²

Affiliation:

1. National Hospital Organization Kyushu Cancer Center Fukuoka Japan

2. National Cancer Center Hospital East Kashiwa Japan

3. Novartis Pharma K.K. Tokyo Japan

4. Novartis Institute for Biomedical Research Shanghai China

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13956

Reference29 articles.

1. Met, metastasis, motility and more

2. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

3. c-MET as a potential therapeutic target and biomarker in cancer

4. MET As a Possible Target for Non–Small-Cell Lung Cancer

5. Targeting the c-Met Pathway Potentiates Glioblastoma Responses to γ-Radiation

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions;Cells;2024-01-25

2. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives;Cancer Management and Research;2023-11

3. Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds;Cancers;2023-08-05

4. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review;Cancers;2023-07-10

5. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16